NCT01492088View on ClinicalTrials.gov

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 16, 2012

Primary Completion Date

October 12, 2016

Study Completion Date

April 12, 2018

Conditions
Relapsed or Refractory Hodgkin LymphomaRelapsed or Refractory Anaplastic Large-cell Lymphoma
Interventions
DRUG

Brentuximab vedotin

Brentuximab vedotin IV infusion

Trial Locations (18)

Unknown

Aurora

Kansas City

New York

Houston

Bordeaux

Lyon

Paris

Berlin

Frankfurt

Giessen

Halle

Münster

Padua

Roma

Mexico City

Rotterdam

Barcelona

London

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY